http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104803989-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c0152623cff45c7c58e9c47b65ea4ca
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
filingDate 2015-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5065d1bc74ad9a26ef8d6ab24088cfd7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f347195b7948c0f0e5ddc09f49232f57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a58f102596382064a14fa05b3955d763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ad82ff5f7e7a409ddb4cd889f40abc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87dc1326ce8256c12beb3a4b28150173
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1fa6702d1196b5de51e9256146bbce5
publicationDate 2015-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-104803989-A
titleOfInvention Bridged ring compounds as hepatitis C inhibitors and their use in medicine
abstract The present invention provides some bridged ring compounds as shown in formula (I) or their stereoisomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs , for the treatment of hepatitis C virus (HCV) infection or hepatitis C disease. The present invention also discloses pharmaceutical compositions containing such compounds and methods of treating HCV infection or hepatitis C disease using the compounds of the present invention or pharmaceutical compositions thereof.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112679407-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112679407-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10428065-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10118920-B2
priorityDate 2014-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012050918-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014019344-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102596936-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466425935
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466234119
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467104122
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467571893
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466193785

Total number of triples: 38.